Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04674280
Other study ID # 8410-016
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date January 2021
Est. completion date January 2025

Study information

Verified date December 2020
Source European Group for Blood and Marrow Transplantation
Contact EBMT ADWP- OMST study coordinator
Phone +33.1.70.64.24.16
Email manuela.badoglio@upmc.fr
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Observational prospective , multi-center study Primary objective : To gain further homogenous evidence for clinical efficacy of aHSCT in patients undergoing aHSCT for MS as primary indication. Secondary objectives: - Safety, tolerability and toxicity of aHSCT in MS - Quality of life and long-term disability after aHSCT - MRI outcome after aHSCT Primary endpoint : Time to failure to maintain a NEDA status Secondary endpoints: - Overall survival - Transplant related mortality - MRI Assessment including lesions - Treatment-related complications . • Quality of life through the MS QL 54 standard assessment - Improvement of disability Inclusion criteria: - Diagnosis of MS according to the 2010 revision McDonald's criteria - Availability of a detailed clinical history about MS, including progression of disability and relapse rate in the previous 2 years, previous treatments administered - Patients aged 18yrs or over at the time of the first aHSCT Exclusion criteria: - Lack of one of the above criteria - Physical, mental, or social condition which could affect the patient from returning for follow-up visits - Patients with cognitive impairments, who are unable to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are considered part of routine patient care. Recruitment: 50 patients Recruitment period: 2 years starting from the inclusion of the 1st patient Follow-up duration: 2 years


Description:

Currently, a number of new prospective comparative trials have either started or are in preparation, and the EBMT guidelines recommend treatment on a clinical trial, where available. However, some MS patients receiving aHSCT will not be eligible for these trials, which are predominantly focussed on a tightly defined group of patients with highly active RRMS. In addition, access to such trials is not universal across EBMT and therefore there is a need for structured data collection. The investigators propose here to conduct an observational cohort study that systematically gathers experience from MS patients, for whom an adequate set of data about their clinical history and their clinical situation at baseline is available; patients will be then be followed prospectively according to their local clinical center protocol. The expectation is that local clinical protocols will be in line with the current EBMT guidelines and recommendations. Therefore, the aim will be to prospectively and non-interventionally capture a complete dataset to safety, tolerability and efficacy outcomes for aHSCT in various sub-types of MS treated in accordance with the current EBMT guidelines and recommendations. Alongside ongoing clinical trials, the investigators hope this study will meaningfully inform the evidence-base and future guidelines and recommendations for good clinical practice. 1- Study design Multi-centre, non-interventional prospective study in patients diagnosed with Multiple Sclerosis, treated with aHSCT. 2 Aims and objectives of the study 1. Primary objectives - To evaluate the outcome of patients undergoing aHSCT for MS as primary indication. 2. Secondary objectives - To gain further knowledge on safety, tolerability and toxicity of aHSCT in MS - To gain further knowledge on the quality of life and long-term disability of patients treated with aHSCT - To gain further knowledge about the MRI outcome after aHSCT 3. Study schedule The clinical assessment at enrolment and during follow-up will be carried out according to local policies, with the expectation that centres will be working in line with the EBMT Guidelines and Recommendations for MS and immune-mediated neurological diseases. However, based on common clinical practice in patients with MS on therapy, an MRI and one neurological assessment are usually carried out yearly. Baseline MRI should be carried out within 3 months before the start of the mobilization regimen, whilst neurological examination should be accomplished as baseline assessment no more than one month before the start of the treatment. Enrolment time is 2 years from the registration of the first patient. Follow-up is anticipated for 24 months from individual start of treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 50
Est. completion date January 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Diagnosis of MS according to McDonald's criteria - Availability of a detailed clinical history about MS, including progression of disability and relapse rate in the previous 2 years, treatments administered before aHSCT, and categorization of the sub-types of MS according to current EBMT guidelines - Highly active relapsing remitting MS failing DMTs - Progressive MS with active inflammatory component. In accordance with the EBMT guidelines, this category includes both secondary and primary progressive MS with active inflammatory component. - Aggressive (malignant) MS not previously treated with a full course of DMT - Patients aged 18 or over at time of first aHSCT - Signed informed consent Exclusion Criteria: - Lack of one of the above criteria - Progressive MS without active inflammatory component, as this indication is assigned 'GNR' according to EBMT guidelines, irrespective of whether it is secondary or primary progressive. - Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that is likely to affect the patient be able to return for the scheduled follow-up visits. - Patients with cognitive impairments, who are unable to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are considered part of routine patient care.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
aHSCT
Autologous haematopoietic stem cell transplantation

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
European Group for Blood and Marrow Transplantation

Outcome

Type Measure Description Time frame Safety issue
Primary Time to NEDA-3 failure NEDA-3 is defined as a composite endpoint including survival without relapses, disability progression and MRI activity (new or enlarging T2 lesions or Gd-enhancing lesions on MRI). 4 years
Secondary Overall survival Overall survival (OS), is defined as the interval between the date of aHSCT and either the last follow-up visit or the date of death from any cause. 4 years
Secondary Transplant related mortality Treatment related mortality (TRM) defined as any death following transplant that cannot be attributed to progression or relapse of the disease. 4 years
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03269175 - BENEFIT 15 Long-term Follow-up Study of the BENEFIT and BENEFIT Follow-up Studies Phase 4